Literature DB >> 31009109

Chimeric antigen receptor T cell persistence and memory cell formation.

Alexander D McLellan1, Seyed M Ali Hosseini Rad1.   

Abstract

It is now becoming clear that less differentiated naive and memory T cells are superior to effector T cells in the transfer of immunity for adoptive cell therapy. This review will outline the challenges faced by chimeric antigen receptor (CAR) T cell therapy in the generation of persistence and memory for CAR T cells, and summarize recent strategies to improve CAR T cell persistence, with a focus on memory cell formation. The relevance of enhancing persistence in more differentiated effector T cells is also covered, because genetic and pharmacological interventions may prolong effector T cell activity and lifespan, thereby improving anti-cancer activity. In particular, it may be possible to enforce epigenetic changes in differentiated T cells to enhance memory CAR T cell formation. Optimizing the generation of self-renewing T cell populations (e.g. memory cells), while maintaining differentiated effector T cells through epigenome modification, will help overcome barriers to T cell expansion and survival, thereby improving clinical outcomes in CAR T cell therapy.
© 2019 Australian and New Zealand Society for Immunology Inc.

Entities:  

Keywords:  CAR T cells; adaptive immunity; cancer; cellular immunity; immunological memory; immunology; innate immune cells; persistence

Mesh:

Substances:

Year:  2019        PMID: 31009109     DOI: 10.1111/imcb.12254

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  61 in total

1.  Optimization of Culture Conditions for the Generation of Canine CD20-CAR-T Cells for Adoptive Immunotherapy.

Authors:  Osamu Sakai; Hiroka Yamamoto; Masaya Igase; Takuya Mizuno
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

Review 2.  Chimeric antigen receptor T-cell therapies: Optimising the dose.

Authors:  Nathaniel Dasyam; Philip George; Robert Weinkove
Journal:  Br J Clin Pharmacol       Date:  2020-03-24       Impact factor: 4.335

Review 3.  Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?

Authors:  Mattia D'Agostino; Noopur Raje
Journal:  Leukemia       Date:  2019-11-28       Impact factor: 11.528

Review 4.  Immunotherapy of multiple myeloma.

Authors:  Simone A Minnie; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

5.  T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.

Authors:  Geoffrey Parriott; Kelsey Deal; Shane Crean; Elle Richardson; Emily Nylen; Amorette Barber
Journal:  Immunology       Date:  2020-04-07       Impact factor: 7.397

6.  SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models.

Authors:  Axel Hyrenius-Wittsten; Yang Su; Minhee Park; Julie M Garcia; Josef Alavi; Nathaniel Perry; Garrett Montgomery; Bin Liu; Kole T Roybal
Journal:  Sci Transl Med       Date:  2021-04-28       Impact factor: 17.956

7.  Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.

Authors:  Jinhuan Xu; Xi Ming; Chunyan Wang; Bi Xu; Yi Xiao
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

8.  90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma.

Authors:  William I Bensinger; Damian J Green; Sherilyn A Tuazon; Brenda M Sandmaier; Theodore A Gooley; Darrell R Fisher; Leona A Holmberg; Pamela S Becker; Sally J Lundberg; Johnnie J Orozco; Ajay K Gopal; Brian G Till; David G Coffey; Margaret E Nartea; Manuela C Matesan; John M Pagel; Joseph G Rajendran; Oliver W Press
Journal:  Bone Marrow Transplant       Date:  2020-07-24       Impact factor: 5.483

Review 9.  Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.

Authors:  Taewoong Choi; Yubin Kang
Journal:  Pharmacol Ther       Date:  2021-09-25       Impact factor: 13.400

10.  Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models.

Authors:  Brian Webster; Ying Xiong; Peirong Hu; Darong Wu; Leah Alabanza; Rimas J Orentas; Boro Dropulic; Dina Schneider
Journal:  Mol Ther       Date:  2021-05-08       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.